

DOCKET NO.: ISIS0053-100 (RTS-0182)**PATENT****REMARKS**

Claims 1, 2, 4-10, and 12-15 were pending in the present application. Claims 1, 2, 4-10, and 12-15 have been canceled without prejudice to their presentation in another application. New claims 21-39 have been added. No new matter has been added. Upon entry of the present amendment, claims 21-39 will be pending.

Although Applicants disagree with the assertions in the Advisory Action and maintain that claims 1, 2, 4-10, and 12-15 should be allowed, solely to advance prosecution of the present application, new claims have been presented herein.

New claim 21 recites an oligomeric compound up to 50 nucleobases in length comprising SEQ ID NO:73, or a pharmaceutically acceptable salt thereof, support for which can be found at, for example, page 4, lines 30-35 (oligomeric compound); page 11, lines 18-24 (reciting that the oligomeric compounds can have as many as 50 nucleobases); page 82, Table 1 (SEQ ID NO:73); and page 22, lines 31-35 (pharmaceutically acceptable salt) of the specification.

New claims 22 and 34 recite an oligonucleotide, support for which can be found at, for example, page 11, lines 3-6 of the specification.

New claim 23 recites at least one modified internucleoside linkage, support for which can be found at, for example, page 12, lines 11-13 of the specification.

New claim 24 recites a phosphorothioate linkage, support for which can be found at, for example, page 12, lines 22-34 of the specification.

New claim 25 recites at least one modified sugar moiety, support for which can be found at, for example, page 14, lines 33-34 of the specification.

New claim 26 recites a 2'-O-CH₂CH₂OCH₃ (also recited in claim 27), 2'-O-CH₃, or 2'-F moiety, support for which can be found at, for example, page 15, lines 32-36 of the specification.

New claim 28 recites at least one modified nucleobase, support for which can be found at, for example, page 16, lines 15-17 of the specification.

New claim 29 recites a 5-methylcytosine, support for which can be found at, for example, page 16, lines 20-35 of the specification.

DOCKET NO.: ISIS0053-100 (RTS-0182)**PATENT**

New claim 30 recites a chimeric oligonucleotide, support for which can be found at, for example, page 20, lines 14-15 of the specification.

New claim 31 recites a chimeric oligonucleotide comprising 2'-O-CH₂CH₂OCH₃ wings and a deoxy gap, support for which can be found in, for instance, Example 15 at pages 80-81 of the specification.

New claim 32 recites the pharmaceutically acceptable salt is a sodium salt or a potassium salt, support for which can be found at, for example, page 22, lines 31-35 of the specification.

New claim 33 recites a composition comprising a pharmaceutically acceptable carrier or diluent, support for which can be found at, for example, page 4, lines 15-17 and at page 24, lines 34-37 of the specification.

New claim 35 recites a colloidal dispersion system, support for which can be found at, for example, original claim 13.

New claim 36 recites another oligonucleotide, support for which can be found at, for example, page 50, lines 10-16 of the specification.

New claim 37 recites a method of inhibiting the expression of damage-specific DNA binding protein 1, p127 in a cell or a tissue comprising contacting the cell or tissue *in vitro* with the compound of claim 21, wherein the expression of damage-specific DNA binding protein 1, p127 is inhibited, support for which can be found at, for example, original claim 15.


New claim 38 recites a method of detecting the presence of damage-specific DNA binding protein 1, p127 in a cell or a tissue comprising contacting the cell or tissue *in vitro* with the compound of claim 21 and detecting the presence of the compound, support for which can be found at, for example, page 25, lines 4-16 of the specification.

New claim 39 recites a kit, support for which can be found at, for example, page 9, lines 26-31 of the specification.

DOCKET NO.: ISIS0053-100 (RTS-0182)**PATENT**

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. None of the claimed subject matter is obvious in view of the references of record. An early notice of the same is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at (215) 665-6914 if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,


Paul K. Legaard, Ph.D.
Registration No. 38,534

Date: 2 July 2004

COZEN O'CONNOR, P.C.
1900 Market Street
Philadelphia, PA 19103-3508
Telephone: (215) 665-6914
Facsimile: (215) 701-2141